Altered TERT promoter and other genomic regulatory elements: occurrence and impact

Study of genetic alterations, inherited or acquired, that increase the risk or drive cancers and many other diseases had remained mostly confined to coding sequences of the human genome. Data from genome wide associations studies, development of the Encyclopedia of DNA Elements (ENCODE), and a spurt in detection of driver somatic mutations have shifted focus towards noncoding regions of the human genome. The majority of genetic variants robustly associated with cancers and other syndromes identified through genome wide studies are located within noncoding regulatory regions of the genome. Genome wide techniques have put an emphasis on the role of three‐dimensional chromosomal structures and cis‐acting elements in regulations of different genes. The variants within noncoding genomic regions can potentially alter a number of regulatory elements including promoters, enhancers, insulators, noncoding long RNAs and others that affect cancers and various diseases through altered expression of critical genes. With effect of genetic alterations within regulatory elements dependent on other partner molecules like transcription factors and histone marks, an understanding of such modifications can potentially identify extended therapeutic targets. That concept has been augmented by the detection of driver somatic noncoding mutations within the promoter region of the telomerase reverse transcriptase (TERT) gene in different cancers. The acquired somatic noncoding mutations within different regulatory elements are now being reported in different cancers with an increased regularity. In this review we discuss the occurrence and impact of germline and somatic alterations within the TERT promoter and other genomic regulatory elements.

[1]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[2]  A. Dobrovic,et al.  Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies , 2016, Oncotarget.

[3]  D. Schadendorf,et al.  Analysis of SDHD promoter mutations in various types of melanoma , 2015, Oncotarget.

[4]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.

[5]  R. Young,et al.  APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL , 2017, Leukemia.

[6]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[7]  Nam Huh,et al.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway , 2015, Nature Genetics.

[8]  Jun S. Song,et al.  Understanding TERT Promoter Mutations: A Common Path to Immortality , 2016, Molecular Cancer Research.

[9]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[10]  C. Copie-Bergman,et al.  MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.

[11]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[12]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[13]  F. Izzo,et al.  Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma , 2016, Oncotarget.

[14]  C. Larsson,et al.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas , 2014, Oncogene.

[15]  J. Calderaro,et al.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[16]  Miguel Melo,et al.  Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.

[17]  K. Hoang-Xuan,et al.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.

[18]  C. Bassing,et al.  Genomic Alterations of Non-Coding Regions Underlie Human Cancer: Lessons from T-ALL. , 2016, Trends in molecular medicine.

[19]  W. Chng,et al.  Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas , 2016, Proceedings of the National Academy of Sciences.

[20]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[21]  Y. Jeng,et al.  TERT promoter mutation is uncommon in acral lentiginous melanoma , 2014, Journal of cutaneous pathology.

[22]  S. Hinrichs,et al.  Structural evidence for the authenticity of the human retinoblastoma gene. , 1987, Science.

[23]  Douglas F Easton,et al.  Genome-wide association studies in common cancers--what have we learnt? , 2010, Current opinion in genetics & development.

[24]  S. Boulton,et al.  Molecular basis of telomere dysfunction in human genetic diseases , 2015, Nature Structural &Molecular Biology.

[25]  D. Schadendorf,et al.  TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2014, Modern Pathology.

[26]  E. Zwarthoff,et al.  Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. , 2014, Investigative ophthalmology & visual science.

[27]  Miguel Manzanares,et al.  Allelic Variation at the 8q23.3 Colorectal Cancer Risk Locus Functions as a Cis-Acting Regulator of EIF3H , 2010, PLoS genetics.

[28]  Len A. Pennacchio,et al.  Enhancer Variants Synergistically Drive Dysfunction of a Gene Regulatory Network In Hirschsprung Disease , 2016, Cell.

[29]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[30]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[31]  Stephen C. J. Parker,et al.  Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants , 2013, Proceedings of the National Academy of Sciences.

[32]  Michael C. Heinold,et al.  A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing , 2015, Nature Communications.

[33]  C. Sander,et al.  Genome-wide analysis of non-coding regulatory mutations in cancer , 2014, Nature Genetics.

[34]  K. Brown,et al.  An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations , 2016, Proteomics.

[35]  Xueda Hu,et al.  Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas , 2014, International journal of cancer.

[36]  Michael R. Green,et al.  Transcriptional regulatory elements in the human genome. , 2006, Annual review of genomics and human genetics.

[37]  Andrew C. Wood,et al.  Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism , 2015, Nature.

[38]  Stephen C. J. Parker,et al.  Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma , 2013, Proceedings of the National Academy of Sciences.

[39]  Jesse R. Dixon,et al.  Topological Domains in Mammalian Genomes Identified by Analysis of Chromatin Interactions , 2012, Nature.

[40]  B. Vogelstein,et al.  Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers , 2015, Genes & development.

[41]  C. Carlson,et al.  Principles for the post-GWAS functional characterization of cancer risk loci , 2011, Nature Genetics.

[42]  J. Bishop,et al.  BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[44]  K. Hemminki,et al.  TERT promoter mutations and telomere length in adult malignant gliomas and recurrences , 2015, Oncotarget.

[45]  P. Hou,et al.  Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers , 2014, International journal of cancer.

[46]  D. Bardin On the ? - ? interaction , 1970 .

[47]  John L Hopper,et al.  Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.

[48]  B. Deplancke,et al.  The Genetics of Transcription Factor DNA Binding Variation , 2016, Cell.

[49]  D. Reich,et al.  Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus , 2009, PLoS genetics.

[50]  E. Campo MYC in DLBCL: partners matter. , 2015, Blood.

[51]  P. Rothberg,et al.  Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma , 2014, Modern Pathology.

[52]  S. Kyo,et al.  Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers , 2008, Cancer science.

[53]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[54]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[55]  C. Larsson,et al.  TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma , 2014, Oncotarget.

[56]  R. C. Poulos,et al.  Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome , 2015, Molecular Cancer Research.

[57]  Dorota H. Sendorek,et al.  Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer , 2016, Nature Genetics.

[58]  Shane J. Neph,et al.  Personal and population genomics of human regulatory variation , 2012, Genome research.

[59]  M. Gerstein,et al.  Role of non-coding sequence variants in cancer , 2016, Nature Reviews Genetics.

[60]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[61]  E. Larsson,et al.  Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.

[62]  J. Bishop,et al.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.

[63]  Mathieu Lupien,et al.  Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. , 2016, Cancer discovery.

[64]  Sandra Krüger,et al.  Melanomas of unknown primary frequently harbor TERT-promoter mutations , 2014, Melanoma research.

[65]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[66]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[67]  K. Hemminki,et al.  TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.

[68]  M. Beckmann,et al.  An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. , 2016, Human molecular genetics.

[69]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .

[70]  Z. Cai,et al.  Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. , 2014, European urology.

[71]  M. Fullwood,et al.  Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation. , 2016, Cancer discovery.

[72]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[73]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[74]  J. Llovet,et al.  TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma. , 2014, Journal of hepatology.

[75]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[76]  A. Nussenzweig,et al.  End-joining, translocations and cancer , 2013, Nature Reviews Cancer.

[77]  Shane J. Neph,et al.  Systematic Localization of Common Disease-Associated Variation in Regulatory DNA , 2012, Science.

[78]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[79]  Gary D Bader,et al.  Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.

[80]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[81]  D. Schadendorf,et al.  TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours , 2013, British Journal of Cancer.

[82]  Christopher A. Haiman,et al.  The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer , 2009, Nature Genetics.

[83]  Britta A. M. Bouwman,et al.  A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.

[84]  Functional analysis of CDKN2A/p16INK4a 5'-UTR variants predisposing to melanoma. , 2010, Human molecular genetics.

[85]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[86]  Stephen J. Chanock,et al.  Current status of genome-wide association studies in cancer , 2011, Human Genetics.

[87]  R. Young,et al.  An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.

[88]  V. Tergaonkar,et al.  Telomerase: central regulator of all of the hallmarks of cancer. , 2013, Trends in biochemical sciences.

[89]  James C. Costello,et al.  TERT promoter mutations and telomerase reactivation in urothelial cancer , 2015, Science.

[90]  J. Boyle,et al.  Cancer-associated TERT promoter mutations abrogate telomerase silencing , 2015, eLife.

[91]  T. Chan,et al.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.

[92]  L. Aaltonen,et al.  Lessons from functional analysis of genome-wide association studies. , 2013, Cancer research.

[93]  Rajiv Kumar,et al.  TERT promoter mutations in telomere biology. , 2017, Mutation research.

[94]  C. Liu,et al.  TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR , 2014, Oncotarget.

[95]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[96]  Adam G Diehl,et al.  Deciphering ENCODE. , 2016, Trends in genetics : TIG.

[97]  Ivana V. Yang,et al.  A common MUC5B promoter polymorphism and pulmonary fibrosis. , 2011, The New England journal of medicine.

[98]  Paolo Vineis,et al.  Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.

[99]  Nazneen Rahman,et al.  Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.

[100]  Esko Ukkonen,et al.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling , 2009, Nature Genetics.

[101]  Deqing Hu,et al.  Enhancer malfunction in cancer. , 2014, Molecular cell.

[102]  J. Ju,et al.  A frequent somatic mutation in CD274 3′‐UTR leads to protein over‐expression in gastric cancer by disrupting miR‐570 binding , 2012, Human mutation.

[103]  K. Dutton-Regester,et al.  A highly recurrent RPS27 5'UTR mutation in melanoma , 2014, Oncotarget.

[104]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[105]  I. Noth,et al.  Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. , 2013, JAMA.

[106]  J. Becker,et al.  Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma , 2014, Nature Communications.

[107]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[108]  J. Taipale,et al.  The role of enhancers in cancer , 2016, Nature Reviews Cancer.

[109]  Rajiv Kumar,et al.  TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation , 2016, Oncotarget.

[110]  S. Tuft,et al.  Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2 , 2015, American journal of human genetics.

[111]  Dawei Xu,et al.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications , 2016, Genes.

[112]  Marc A. Beal,et al.  Whole genome sequencing for quantifying germline mutation frequency in humans and model species: cautious optimism. , 2012, Mutation research.

[113]  L. Aaltonen,et al.  Mice Lacking a Myc Enhancer That Includes Human SNP rs6983267 Are Resistant to Intestinal Tumors , 2012, Science.

[114]  Darell D. Bigner,et al.  Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas , 2014, Oncotarget.

[115]  W. Kim,et al.  Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. , 2016, Thyroid : official journal of the American Thyroid Association.

[116]  D. Schadendorf,et al.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism , 2013, Proceedings of the National Academy of Sciences.

[117]  Keith A. Boroevich,et al.  Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity , 2015, Nature Communications.

[118]  Jessica Zucman-Rossi,et al.  Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.

[119]  D. Schadendorf,et al.  High TERT promoter mutation frequency in non‐acral cutaneous metastatic melanoma , 2016, Pigment cell & melanoma research.

[120]  J. Fallon,et al.  Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. , 2015, Annals of diagnostic pathology.

[121]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[122]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[123]  B. Necela,et al.  Clinical and molecular features of Hürthle cell carcinoma of the thyroid. , 2015, The Journal of clinical endocrinology and metabolism.

[124]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[125]  Th. Boveri Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris , 2008, Journal of Cell Science.

[126]  A. Nordheim,et al.  Frequent DPH3 promoter mutations in skin cancers , 2015, Oncotarget.

[127]  D. Schadendorf,et al.  TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma , 2013, PloS one.

[128]  M. Tucker,et al.  Germline splicing mutations of CDKN2A predispose to melanoma , 2003, Oncogene.

[129]  M. Blasco,et al.  Replicating through telomeres: a means to an end. , 2015, Trends in biochemical sciences.

[130]  J. A. Bishop,et al.  A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. , 2001, Human molecular genetics.

[131]  Marc Fellous,et al.  Donor splice-site mutations in WT1 are responsible for Frasier syndrome , 1997, Nature Genetics.

[132]  Keith A. Boroevich,et al.  Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.

[133]  V. Corces,et al.  Enhancer function: new insights into the regulation of tissue-specific gene expression , 2011, Nature Reviews Genetics.

[134]  Deng Cai,et al.  Recurrent TERT promoter mutations in non-small cell lung cancers. , 2014, Lung cancer.

[135]  Chibo Hong,et al.  The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.

[136]  Nicholas A. Sinnott-Armstrong,et al.  Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer , 2016, Nature Genetics.

[137]  Niko Välimäki,et al.  CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.

[138]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[139]  P. Chandrasekharan,et al.  Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation , 2015, Nature Cell Biology.

[140]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[141]  M. Deininger,et al.  Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.

[142]  M. Honavar,et al.  TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. , 2014, The Journal of investigative dermatology.

[143]  E. Grice,et al.  Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. , 2010, American journal of human genetics.

[144]  K. Hemminki,et al.  Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer , 2015, International journal of cancer.